Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

Description

Persons without a spleen are susceptible to potentially lethal infections from certain bacteria, with pneumococcus being the most prevalent. Vaccines are provided to help protect against these infections, though they do not so with certainty. Trauma patients who sustain an injury to their spleen currently have three treatment options available for the treating surgeon - nonoperative management, embolization, or removal of the spleen. The purpose of this study is to investigate the antibody response to pneumococcal vaccine in patients undergoing these modes of therapy.

Conditions

Asplenia

Study Overview

Study Details

Study overview

Persons without a spleen are susceptible to potentially lethal infections from certain bacteria, with pneumococcus being the most prevalent. Vaccines are provided to help protect against these infections, though they do not so with certainty. Trauma patients who sustain an injury to their spleen currently have three treatment options available for the treating surgeon - nonoperative management, embolization, or removal of the spleen. The purpose of this study is to investigate the antibody response to pneumococcal vaccine in patients undergoing these modes of therapy.

Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

Condition
Asplenia
Intervention / Treatment

-

Contacts and Locations

Sacramento

University of California, Davis Medical Center, Sacramento, California, United States, 95817

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adult trauma patients (aged 18 to 65 years old) sustaining a splenic injury.
  • * Ages less than 18 and greater than 65
  • * Initial planned nonoperative management patient who subsequently undergoes embolization or splenectomy will be withdrawn from the study.

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, Davis,

David Shatz, MD, PRINCIPAL_INVESTIGATOR, University of California, Davis

Study Record Dates

2025-07